Vitamin E succinate (VES) induces Fas sensitivity in human breast cancer cells: Role for M(r) 43,000 Fas in VES-triggered apoptosis

Cancer Research

Volumn 59, Issue 4, 1999, Pages 953-961

  Yu, Weiping ^a   Israel, Karen ^a   Liao, Qiao Yin ^a   Aldaz, C Marcelo ^b   Sanders, Bob G ^a   Kline, Kimberly ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL SUCCINATE; ANTIBODY; FAS ANTIBODY; FAS ANTIGEN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CELL IMMORTALIZATION; CELLULAR DISTRIBUTION; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG POTENTIATION; GENE EXPRESSION; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR RESISTANCE;

ANTIGENS, CD95; APOPTOSIS; BREAST NEOPLASMS; FEMALE; HUMANS; INTERFERON TYPE II; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE KINASE 4; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MOLECULAR WEIGHT; PROTEIN KINASES; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED; VITAMIN E;

EID: 0033557969     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Kelloff, G., Crowell, J. A., Boone, C. W., Steele, V. E., Lubet, R. A., Greenwald, P., Alberts, D. S., Covey, J. M., Doody, L. A., Knapp, G. G., Nayfield, S., Parkinson, D. R., Prasad, V. K., Prorok, P. C., Sausville, E. A., and Sigman, C. C. Clinical development plans for cancer chemopreventive agents: vitamin E. J. Cell. Biochem., 20: 282-294, 1994.
2. Charpentier, A., Groves, S., Simmons-Menchaca, M., Turley, J., Zhao, B., Sanders, B. G., and Kline, K. RRR-α-tocopheryl succinate inhibits proliferation and enhances secretion of transforming growth factor-β (TGF-β) by human breast cancer cells. Nutr. Cancer. 19: 225-239, 1993.
3. Charpentier, A., Simmons-Menchaca, M., Weiping, Y., Zhao, B., Ming, Q., Heim, K., Sanders, B. G. and Kline, K. RRR-α-tocopheryl succinate enhances TGF-β1, -β2, -β3 and TGF-βR-II expression by human MDA-MB-435 breast cancer cells. Nutr. Cancer. 26: 237-250, 1996.
4. Schwartz, J., and Shklar, G. The selective cytotoxic effect of carotenoids and α-tocopherol on human cancer cell lines in vitro. J. Oral Maxillofac. Surg., 50: 367-373, 1992.
5. Kline, K., Yu, W., Zhao, B., Israel, K., Charpentier, A., Simmons-Menchaca, M., and Sanders, B. G. Vitamin E succinate. Mechanisms of action as tumor cell growth inhibitor. In: K. N. Prasad, L. Santamaria, and R. M. Williams (eds.), Nutrients in Cancer Prevention and Treatment, pp. 189-205. Totowa, NJ: Humana, 1995.
6. Kline, K., Yu, W., and Sanders, B. G. Vitamin E: mechanisms of action as tumor cell growth inhibitors. In: K. N. Prasad and W. C. Cole (eds.), Proceedings of the International Conference on Nutrition and Cancer, pp. 37-53. Amsterdam: IOS Press, 1998.
7. Kline, K., Cochran, G. S., and Sanders, B. G. Growth-inhibitory effects of vitamin E succinate on retrovirus-transformed tumor cells in vitro. Nutr. Cancer, 14: 27-41, 1990.
8. Turley, J. M., Sanders, B. G., and Kline, K. RRR-α-tocopheryl succinate modulation of human promyelocytic leukemia (HL-60) cell proliferation and differentiation. Nutr. Cancer, 18: 201-213, 1992.
9. Simmons-Menchaca, M., Qian, M., Yu, W., Sanders, B. G., and Kline, K. RRR-α-tocopheryl succinate inhibits DNA synthesis and enhances the production and secretion of biologically active transforming growth factor-β (TGF-β) by avian retrovirus-transformed lymphoid cells. Nutr. Cancer, 24: 171-185, 1995.
10. Prasad, K. N., Cohrs, R. J., and Sharma, O. K. Decreased expression of c-myc and H-ras oncogenes in vitamin E succinate induced morphologically differentiated murine B-16 melanoma cells in culture. Cell Biol., 68: 1250-1255, 1990.
11. Cohrs, R. J. Torelli, S., Prasad, K. N., Edwards-Prasad, J., and Sharma, O. K. Effect of vitamin E succinate and a cAMP-stimulating agent on the expression of c-myc, N-myc, and H-ras in murine neuroblastoma cells. Int. J. Dev. Neurosci., 9: 187-194, 1991.
12. Turley, J. M., Funakoshi, S., Ruscetti, F. W., Kasper, J., Murphy, W. J., Longo, D. L., and Birchenall-Roberts, M. C. Growth inhibition and apoptosis of RL human B lymphoma cells by vitamin E succinate and retinoic acid: role for transforming growth factor β. Cell Growth Differ., 6: 655-663, 1995.
13. Qian, M., Sanders, B. G., and Kline, K. RRR-α-tocopheryl succinate induces apoptosis in avian retrovirus-transformed lymphoid cells. Nutr. Cancer, 25: 9-26, 1996.
14. Israel, K., Sanders, B. G., and Kline, K. RRR-α-tocopheryl succinate inhibits the proliferation of human prostatic tumor cells with defective cell cycle/differentiation pathways. Nutr. Cancer, 24: 161-169, 1995.
15. Yu, W., Heim, K., Qian, M., Simmons-Menchaca, M., Sanders, B. G., and Kline, K. Evidence for role of transforming growth factor-β in RRR-α-tocopheryl succinate-induced apoptosis of human MDA-MB-435 breast cancer cells. Nutr. Cancer, 27: 267-278, 1997.
16. Zhao, B., Yu, W., Qian, M. Simmons-Menchaca, M., Brown, P., Birrer, M. J., Sanders, B. G., and Kline, K. Involvement of activator protein-1 (AP-1) in induction of apoptosis by vitamin E succinate in human breast cancer cells. Mol. Carcinog., 19: 180-190, 1997.
17. Yu, W., Simmons-Menchaca, M., You, H., Brown, P., Birrer, M. J., Sanders, B. G., and Kline, K. RRR-α-tocopheryl succinate induction of prolonged activation of c-Jun amino-terminal kinase and c-Jun during induction of apoptosis in human MDA-MB-435 breast cancer cells. Mol. Carcinog., 22: 247-257, 1998.
18. Turley, J. M,. Fu, T., Ruscetti, F. W., Mikovits, J. A., Bertolette, D. C., III, and Birchenall-Roberts, M. C. Vitamin E succinate induces Fas-mediated apoptosis in estrogen receptor-negative human breast cancer cells. Cancer Res., 57: 881-890, 1997.
19. Nagata, S., and Goldstein, P. The Fas death factor. Science (Washington DC), 267: 1449-1456, 1995.
20. Itoh, N., Yonehara, S., Ishii, A., Yonehara, M., Mizushima, S. I., Sameshima, M., Hase, A., Seto, Y., and Nagata, S. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell, 66: 233-243, 1991.
21. Rudert, F., Visser, E., Forbes, L., Lindridege, E., Wang, Y., and Watson, J. Identification of a silencer enhancer, and basal promoter region in the human CD95 (Fas/APO-1) gene. DNA Cell Biol., 14: 931-937, 1995.
22. Shen, K., and Novak, R. F. Fas signaling and effects on receptor tyrosine kinase signal transduction in human breast epithelial cells. Biochem. Biophys. Res. Commun., 230: 89-93, 1997.
23. Keane, M. M., Ettenberg, S. A., Lowrey, G. A., Russell, E. K., and Lipkowitz, S. Fas expression and function in normal and malignant breast cell lines. Cancer Res., 56: 4791-4798, 1996.
24. Weller, M., Frei, K., Groscurth, P., Krammer, P. H., Yonekawa, Y., and Fontana, A. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. J. Clin. Invest., 94: 954-964, 1994.
25. Takeuchi, T. Sasaki, Y., Ueki, T., Kaziwara, T., Moriyama, N., Kawab, K., and Kakizoe, T. Modulation of growth and apoptosis response in PC-3 and LNCaP prostate-cancer cell lines by Fas. Int. J. Cancer. 67: 709-714, 1996.
26. Bargou, R. C., Wagener, C. Bommert, K., Mapara, M. Y., Daniel, P. T., Arnold, W., Dietel, M., Guski, H., Feller, A., Royer, H. D., and Dorken, B. Overexpression of the death-promoting gene bax-α which is downregulated in breast cancer restores sensitivity to different apoptolic stimuli and reduces tumor growth in SCID mice. J. Clin. Invest., 97: 2651-2659, 1996.
27. Rokhlin, O. W., Bishop, G. A., Hostager, B. S., Waldschmidt, T. J., Sidorenko, S. P., Pavloff, N., Kiefer, M. C., Umansky, S. R., Glover, R. A., and Cohen, M. B. Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res., 57: 1758-1768, 1997.
28. Leithauser, F., Dhein, J., Mechtesheimer, G., Koretz, K., Bruderlein, S., Henne, C., Schmidt, A., Debatin, K-M., Krammer, P. H., and Moller, P. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab. Invest., 69: 415-429, 1993.
29. Moller, P., Koretz, K., Leithauser, F., Bruderlein, S., Henne, C., Quentmeier, A., and Krammer, P. H. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int. J. Cancer, 57: 371-377, 1994.
30. Steller, H. Mechanisms and genes of cellular suicide. Science (Washington DC), 267: 1445-1449, 1995.
31. Kroemer, G., Petit, X., Zamzami, N., Vayssiere, J-L., and Mignotte, B. The biochemistry of apoptosis. FASEB J., 9: 1277-1287, 1995.
32. Thompson, C. B. Apoptosis in the pathogenesis and treatment of disease. Science (Washington DC), 267: 1456-1462, 1995.
33. Kroemer, G., Zamzami, N., and, Susin, S. A. Mitochondrial control of apoptosis. Immunol. Today, 18: 44-51, 1997.
34. Dallaporta, B., Hirsch, T., Susin, S. A., Zamzami, N., Larochette, N., Brenner, C., Marzo, I., and Kromer, G. Potassium leakage during the apoptotic degradation phase. J. Immunol., 160: 5605-5615, 1998.
35. Hughes, S. J., Nambu, Y., Soldes, O. S., Hamstra, D., Rehemtulla, A., Iannettoni, M. D., Orringer, M. B., and Beer, D. G. Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma. Cancer Res., 57: 5571-5578, 1997.
36. Landowski, T. H., Gleason-Guzman, M. C., and Dalton, W. S. Selection for drug resistance results in resistance to Fas-mediated apoptosis. Blood, 89: 1854-1861, 1997.
37. Roth, W., Fontana, A., Trepel, M., Reed, J. C., Dichgans, J., and Welter, M. Immunochemotherapy of malignant glioma: synergistic activity of CD95 ligand and chemotherapeutics. Cancer Immunol. Immunother., 44: 55-63, 1997.
38. Price, J. E., Polyzos, A., Zhang, R. D., and Daniels, L. M. Tumorigenicity and metastasis of human breast cancer carcinoma cell lines in nude mice. Cancer Res., 50: 717-721, 1990.
39. Klotz, D. M., Castles, C. G., Fuqua, S. A. W., Spriggs, L. L. and Hill, S. M. Differential expression of wildtype and variant ER mRNAs by stocks of MCF-7 breast cancer cells may account for differences in estrogen responsiveness. Biochem. Biophys. Res. Commun., 210: 609-615, 1995.
40. Koli, K. M., and Arteaga, C. L. Predominant cytosolic location of type II transforming growth factor β receptors in human breast carcinoma cells. Cancer Res., 57: 970-977, 1997.
41. Chanmugam, P., Feng, L., Liou, S., Jang, B. C., Boudreau, M., Yu, G., Lee, J. H., Kwon, H. J., Beppu, T., Yoshida, M., Xia, Y., Wilson, C. B., and Hwang, D. Radicicol, a protein tyrosine kinase inhibitor, suppresses the expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide and in experimental glomerulonephritis. J. Biol. Chem., 270: 5418-5423, 1995.
42. O'Connell, J., Bennett, M. W., O'Sullivan, G. C. Collins, J. K., and Shanahan, F. The Fas counterattack: a molecular mechanism of tumor immune privilege. Mol. Med., 3: 294-300, 1997.
43. Holmstrom, T. H., Chow, S. C., Elo, I., Coffey, H. T., Orrenius, S., Sistonen, L., and Eriksson, J. E. Suppression of Fas/APO-1-mediated apoptosis by mitogen-activated kinase signaling. J. Immunol., 160: 2626-2636, 1998.
44. Ungefroren, H., Voss, M., Jansen, M., Roeder, C., Henne-Bruns, D., Kremer, B., and Kalthoff, H. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res., 58: 1741-1749, 1998.
45. Bennett, M. W., O'Connell, J., O'Sullivan, G. C., Brady, C. Roche, D., Collins, J. K., and Shanahan, F. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J. Immunol., 160: 5669-5675, 1998.
46. Herr, I., Wilhelm, D., Bohler, T., Angel, P., and Debatin, K-M. Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis. EMBO J., 16: 6200-6208, 1997.
47. Ashley, D. M., Kong, F. M., Bigner, D. D., and Hale, L. P. Endogenous expression of transforming growth factor β1 inhibits growth and tumorigenicity and enhances Fas-mediated apoptosis in a murine high-grade glioma model. Cancer Res., 58: 302-309, 1998.
48. Oehm, A., Behrmann, I., Falk, W., Pawlita, M., Maier, G., Klas, C., Li-Weber, M., Richards, S., Dhein, J., Trauth, B. C., Ponsting, H., and Krammer, P. H. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. J. Biol. Chem., 267: 10709 10715, 1992.
49. Goillot, E., Raingeaud, J., Ranger, A., Tepper, R. I., Davis, R. J., Harlow, E., and Sanchez, I. Mitogen-activated protein kinase-mediated Fas apoptotic signaling pathway. Proc. Natl. Acad. Sci. USA, 94: 3302-3307, 1997.
50. Wilson, D. J., Fortner, K. A., Lynch, D. H., Mattingly, R. R., Macara, I. G., Posada, J. A., and Budd, R. C. JNK, but not MAPK, activation is associated with Fas-mediated apoptosis in human T cells. Eur. J. Immunol., 26: 989-994, 1996.
51. Lenczowski, J. M., Dominguez, L., Eder, A. M., King, L. B. Zacharchuk, C. M., and Ashwell, J. D. Lack of a role for jun kinase and AP-1 in Fas-induced apoptosis. Mol. Cell. Biol., 17: 170-181, 1997.
52. Yang, X., Khosravi-Far, R., Chang, H. Y., and Baltimore, D. Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell, 89: 1067-1076, 1997.
53. Bennett, M., Macdonald, K., Chan, S-W., Luzio, J. P., Simari, R., and Weissberg, P. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science (Washington DC), 282: 290-293, 1998.
54. Nielsen, L. L., Dell, J., Maxwell, E., Armstrong, L., Maneval, D., and Catino, J. J. Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts. Cancer Gene Ther., 4: 129-138, 1997.